Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Urology
•
Rheumatology
•
Rheumatoid Arthritis
•
General Rheumatology
•
Infectious Disease
How do you approach management of DMARDs and biologics in a patient with active RA, but frequent recurrent simple UTIs?
Related Questions
Are you comfortable trying a different JAK inhibitor in patients with prior JAK inhibitor allergy?
Are you comfortable with using NSAIDs in a patient on methotrexate for inflammatory arthritis?
Is there a role for nitazoxanide for treatment of norovirus gastroenteritis in immunocompromised patients?
When considering a biologic for seropositive RA after failure of methotrexate or triple therapy, do you consider using abatacept as a first line biologic or would prefer choosing TNFi?
How would you manage a patient with hidradenitis suppurativa and inflammatory arthritis (RA vs. PsA)?
Are there concerns with combining anti-IL5 biologics (mepolizumab or benralizumab) for severe asthma with other biologics for RA (e.g. TNFi)?
What is your approach to assessing inflammatory arthritis flares in joints that have been replaced (such as knees)?
How do you approach ongoing screening for TB in patients with a history of treated latent TB, but who have ongoing use of DMARDs and/or biologics given Quantiferon testing and PPD can remain positive?
What is your approach to work up for patients referred for early onset osteoarthritis?
How do you approach treating a patient with RA and cirrhosis who did not respond to csDMARDs?
